The ABCC5 Knockout Huh-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Huh-7 hepatocellular carcinoma line, with targeted disruption of the ABCC5 gene encoding the multidrug resistance-associated protein 5 (MRP5) transporter. This polyclonal product contains a heterogeneous mix of edited alleles, providing a robust population-level loss-of-function model that eliminates MRP5-mediated efflux without requiring single-cell cloning.
The Huh-7 cell line is a well-differentiated hepatocellular carcinoma model established from a liver tumor, retaining key hepatocytic features such as metabolic enzyme expression and hepatitis C virus permissiveness. Its widespread use in liver cancer biology, drug metabolism, and ABC transporter research makes it an optimal host for examining the specific contribution of ABCC5 to hepatic drug resistance and cyclic nucleotide homeostasis.
ABCC5 functions as an ATP-driven efflux pump for cyclic nucleotides (cAMP, cGMP) and nucleoside analog chemotherapeutics. Its transcription is controlled by NRF2/NFE2L2 and modulated by TGF-beta and TNF-alpha. At the membrane, ABCC5 interacts with PDZK1, NHERF1, ERM proteins, and caveolin-1, which regulate its activity. By exporting cAMP and cGMP, ABCC5 suppresses PKA and PKG signaling and CREB-dependent transcription, while drug efflux fosters multidrug resistance. Knockout thus restores cyclic nucleotide signaling and drug sensitivity.
In the context of hepatocellular carcinoma, ABCC5 is frequently overexpressed and contributes to the development of resistance to multiple anticancer agents. This polyclonal knockout Huh-7 model therefore serves as a critical tool for dissecting the transporter??s role in treatment failure, allowing direct comparison with parental Huh-7 cells in drug sensitivity and signaling studies. The polyclonal nature captures a spectrum of CRISPR-induced mutations, providing a more comprehensive functional assessment than single-clone isolates and reducing the risk of clonal artifacts. Moreover, this model permits the investigation of MRP5 within the broader hepatic ABC transporter network and its interplay with stress pathways implicated in cancer progression.
Researchers can employ these cells in a variety of assays, including multidrug resistance reversal assays with doxorubicin or 5-fluorouracil, quantitative determination of cAMP and cGMP via ELISA, and phospho-PKA substrate western blotting to assess downstream kinase activation. Flow cytometric analysis using fluorescent substrates like calcein-AM enables direct measurement of MRP5 efflux function, while immunofluorescence microscopy confirms ABCC5 depletion and localization changes of interacting proteins. Transcriptomic studies by RNA-seq illuminate global pathway alterations following knockout, and co-immunoprecipitation can probe protein interaction dynamics. The cells are also suitable for screening of MRP5-specific inhibitors and for exploring the crosstalk between oxidative stress, NRF2 signaling, and drug efflux. For additional product information or technical consultation, please contact Ascent Research.
